Evaluation of High Cholesterol and Risk of Dementia and Cognitive Decline in Older Adults Using Individual Patient Meta-Analysis.


Journal

Dementia and geriatric cognitive disorders
ISSN: 1421-9824
Titre abrégé: Dement Geriatr Cogn Disord
Pays: Switzerland
ID NLM: 9705200

Informations de publication

Date de publication:
2021
Historique:
received: 02 07 2021
accepted: 06 09 2021
pubmed: 27 10 2021
medline: 15 12 2021
entrez: 26 10 2021
Statut: ppublish

Résumé

Although increased cholesterol level has been acknowledged as a risk factor for dementia, evidence synthesis based on published data has yielded mixed results. This is especially relevant in older adults where individual studies report non-linear relationships between cholesterol and cognition and, in some cases, find higher cholesterol associated with a lower risk of subsequent cognitive decline or dementia. Prior evidence synthesis based on published results has not allowed us to focus on older adults or to standardize analyses across studies. Given our ageing population, an increased risk of dementia in older adults, and the need for proportionate treatment in this age group, an individual participant data (IPD) meta-analysis is timely. We combined data from 8 studies and over 21,000 participants aged 60 years and over in a 2-stage IPD to examine the relationship between total, high-density, and low-density lipoprotein (HDL and LDL) cholesterol and subsequent incident dementia or cognitive decline, with the latter categorized using a reliable change index method. Meta-analyses found no relationship between total, HDL, or LDL cholesterol (per millimoles per litre increase) and risk of cognitive decline in this older adult group averaging 76 years of age. For total cholesterol and cognitive decline: odds ratio (OR) 0.93 (95% confidence interval [CI] 0.86: 1.01) and for incident dementia: OR 1.01 [95% CI 0.89: 1.13]. This was not altered by rerunning the analyses separately for statin users and non-users or by the presence of an APOE e4 allele. There were no clear consistent relationships between cholesterol and cognitive decline or dementia in this older adult group, nor was there evidence of effect modification by statin use. Further work is needed in younger populations to understand the role of cholesterol across the life-course and to identify any relevant intervention points. This is especially important if modification of cholesterol is to be further evaluated for its potential influence on risk of cognitive decline or dementia.

Identifiants

pubmed: 34700321
pii: 000519452
doi: 10.1159/000519452
doi:

Substances chimiques

Cholesterol 97C5T2UQ7J

Types de publication

Meta-Analysis Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

318-325

Subventions

Organisme : Medical Research Council
ID : G0500997
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J50001X/1
Pays : United Kingdom

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Ruth Peters (R)

Neuroscience Research Australia, Sydney, New South Wales, Australia.
School of Psychology, University of New South Wales, Sydney, New South Wales, Australia.

Ying Xu (Y)

Neuroscience Research Australia, Sydney, New South Wales, Australia.
School of Psychology, University of New South Wales, Sydney, New South Wales, Australia.

Riitta Antikainen (R)

Faculty of Medicine, Oulu University, Oulu, Finland.

Nigel Beckett (N)

Guys and St Thomas' NHS Trust, London, United Kingdom.

Jacobijn Gussekloo (J)

Leiden University Medical Center, Leiden, The Netherlands.

Carol Jagger (C)

Faculty of Medical Sciences, University of Newcastle, Newcastle upon Tyne, United Kingdom.

Johan Wouter Jukema (JW)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
Netherlands Heart Institute, Utrecht, The Netherlands.

Sirkka Keinanen-Kiukaanniemi (S)

Faculty of Medicine, Oulu University, Oulu, Finland.

Lina Rydén (L)

Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health (AgeCap) at the University of Gothenburg, Gothenburg, Sweden.
Department of Psychiatry Cognition and Old Age Psychiatry, Sahlgrenska University Hospital, Region Västra Götaland, Mölndal, Sweden.

Ingmar Skoog (I)

Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health (AgeCap) at the University of Gothenburg, Gothenburg, Sweden.

Jan A Staessen (JA)

Research Institute Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium.
Biomedical Sciences Group, Faculty of Medicine, University of Leuven, Leuven, Belgium.

Lutgarde Thijs (L)

Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium.

Stella Trompet (S)

Leiden University Medical Center, Leiden, The Netherlands.

Philip J Tully (PJ)

Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France.

Christophe Tzourio (C)

Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France.

Kaarin J Anstey (KJ)

Neuroscience Research Australia, Sydney, New South Wales, Australia.
School of Psychology, University of New South Wales, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH